IP Library Granted Patent US 12,054,751
Granted Patent B2
US 12,054,751 · App. 18/066,303 · Granted Aug 6, 2024

Fucosylation-deficient cells

Inventors: Gang Chen (Yorktown Heights, NY); Darya Burakov (Tarrytown, NY); James P. Fandl (LaGrangeville, NY)
Assignee: Regeneron Pharmaceuticals, Inc.
C12N9/0006C12N15/00C12P21/005C12Y101/01271C07K16/00C07K16/2863C07K16/2866C07K2317/14C07K2317/41Y02P20/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,054,751
App. No.
18/066,303
Granted
Aug 6, 2024
Kind
B2
Abstract

An isolated nucleic acid encoding an FX protein having a serine at position 79, a lysine at position 90, a leucine at position 136, an arginine at position 211, a serine at position 289, and a combination thereof is provided. Cells having a gene encoding a modified FX protein are provided, wherein the cells exhibit a reduced ability to fucosylate a glycoprotein at a first temperature, but exhibit the ability to fucosylate the glycoprotein at a second temperature. Methods and compositions for making glycoproteins with reduced fucosylation are provided.

Claims (16)

1. A method for making a glycoprotein, comprising:

culturing a mammalian cell at a temperature of about 34° C. and in the absence of an external fucose source to express said glycoprotein, wherein the mammalian cell expresses a GDP-4-keto-6-deoxymannose-3,5-epimerase-4-reductase (FX) protein that comprises an amino acid sequence that is at least 95% identical to SEQ ID NO: 1, and wherein the FX protein comprises modification relative to SEQ ID NO: 1, the modification comprising a first amino acid substitution of L289S and a second amino acid substitution selected from the group consisting of N79S, N90K, P136L, and G211R; and

isolating the glycoprotein from the culture.

2. The method of claim 1 , wherein said second amino acid substitution is N90K.

3. The method of claim 1 , wherein said glycoprotein comprises an immunoglobulin CH2 region and an immunoglobulin CH3 region.

4. The method of claim 2 , wherein said glycoprotein comprises an immunoglobulin CH2 region and an immunoglobulin CH3 region.

5. The method of claim 1 , wherein the glycoprotein is an antibody.

6. The method of claim 2 , wherein the glycoprotein is an antibody.

7. The method of claim 1 , wherein said cell is a Chinese hamster ovary (CHO) cell.

8. The method of claim 2 , wherein said cell is a Chinese hamster ovary (CHO) cell.

9. A method for making a glycoprotein, comprising:

culturing a mammalian cell at a temperature of about 34° C. and in the absence of an external fucose source to express said glycoprotein, wherein the mammalian cell expresses an FX protein that comprises an amino acid sequence that is at least 95% identical to SEQ ID NO: 1, and wherein the FX protein comprises modification relative to SEQ ID NO: 1, the modification comprising the amino acid substitution of L289S; and

isolating the glycoprotein from the culture.

10. The method of claim 9 , wherein said glycoprotein comprises an immunoglobulin CH2 region and an immunoglobulin CH3 region.

11. The method of claim 9 , wherein the glycoprotein is an antibody.

12. The method of claim 9 , wherein said cell is a CHO cell.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2024
From: CHEN, GANG; BURAKOV, DARYA; FANDL, JAMES P.
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 067596/0744 →
Continuity (10)
Continuation 17307255 · May 4, 2021
Continuation 16556334 · Aug 30, 2019
Continuation 15987286 · May 23, 2018
Continuation 15378670 · Dec 14, 2016
Continuation 14963178 · Dec 8, 2015
Division 13779952 · Feb 28, 2013
Division 12791637 · Jun 1, 2010
Provisional Application 61348858 · May 27, 2010
Provisional Application 61183400 · Jun 2, 2009
Related Publication 20230295583A1 · Sep 21, 2023